Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CKD-341 vs D958 in Healthy Adults
NCT05921435Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jun 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-341 in hypertension (HTN) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under Curve at 144 hours and Maximum Plasma Concentration at 144 hours. Started Jun 2023; status: completed.
02
Drugs
CKD-341
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05921435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05921435.